Trial · NCT06922591

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591, Phase 1, Phase 2, Recruiting, Tango Therapeutics, Inc.

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients. Trials, record NCT06922591. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06922591

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT number: NCT06922591
Status: Recruiting
Phases: Phase 1, Phase 2
Enrollment: 183 participants, estimated
Lead sponsor: Tango Therapeutics, Inc.
Conditions: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
Interventions: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel
First posted: 2025-04-10
Last updated: 2026-10-23

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Phase 1: Maximum Tolerated Dose	21 days	To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805
Primary	Phase 1: Maximum Tolerated Dose	28 days	To determine the MTD and RD(s) of TNG462 in combination with mFOLFIRINOX or gemcitabine/nab-paclitaxel
Primary	Phase 2: Combination Anti-neoplastic Activity	12 weeks	To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel using RECIST 1.1
Secondary	Phase 1: Combination Anti-neoplastic Activity	12 weeks	To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab paclitaxel using RECIST 1.1
Secondary	Phase 1 and 2: Tmax of TNG462 and in Combination	21 days	To characterize the Tmax of TNG462 in combination with RMC-6236 or RMC-9805
Secondary	Phase 1 and 2: Tmax of TNG462 and in Combination	28 days	To characterize the Tmax of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel
Secondary	Phase 1 and 2: Cmax of TNG462 and in Combination	21 days	To characterize the Cmax of TNG462 in combination with RMC-6236 or RMC-9805
Secondary	Phase 1 and 2: Cmax of TNG462 and in Combination	28 days	To characterize the Cmax of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel
Secondary	Phase 1 and 2: AUC of TNG462 and in Combination	21 days	To characterize the AUC of TNG462 and in combination with RMC-6236 or RMC-9805
Secondary	Phase 1 and 2: AUC of TNG462 and in Combination	28 days	To characterize the AUC of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06922591

GET https://conductscience.org/api/trials/v1/NCT06922591/registered

API reference For AI assistants